Royalty Report: Drugs, Therapeutic, Pharmaceuticals – Collection: 1626


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Pharmaceuticals
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 1626

License Grant
The Company entered into an agreement, as amended, with the Irish University granting the Company an exclusive license for drugs/compounds to half the onset and/or progression of neurodegenerative diseases, in general, and Alzheimer’s Disease, in particular.
Field of Use
The Licensee is in the business of researching, developing and marketing cardiovascular and neurobiology products for commercial development relating to the healthcare industry.

IPSCIO Record ID: 1627

License Grant
The Company entered into a five-year collaboration agreement with the German University to develop therapeutic and anticonvulsant compounds.
Field of Use
Licensee is engaged in researching, developing and marketing cardiovascular and neurobiology products for commercial development.

IPSCIO Record ID: 994

License Grant
An Irish Pharma has cured an unintended breach of its Tysabri (natalizumab) collaboration agreement with another company that had been identified by the US District Court for the Southern District of New York. This affected a previously-announced transaction with a large U.S. based pharma which has now been amended to eliminate in its entirety, the strategic financing and collaboration agreement that was the subject of the Court's 3rd September hearing and the previously-disclosed notice of breach.

Licensee will acquire substantially all of the business, assets and rights related to licensor's Alzheimer's Immunotherapy Program, through a newly-formed company and will initially commit funds to continue the development and launch activities of bapineuzumab, a potential first-in-class treatment that is being evaluated for slowing the progression of Alzheimer's disease, as well as other compounds.

Field of Use
The rights granted apply to the healthcare industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.